Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-04-24
1999-07-06
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514249, 514307, 514311, 514320, 514321, 514322, 514323, 514324, 544353, 546139, 546152, 546196, 546197, 546198, 546199, 546201, 546202, 546205, 424 185, 424 189, C07D40112, C07D21500, A61K 31445
Patent
active
059197978
ABSTRACT:
Halogenated naphthyl methoxy piperidines having a strong affinity for the serotonin transporter are disclosed. Those compounds can be labeled with positron-emitting and/or gamma emitting halogen isotopes by a late step synthesis that maximizes the useable lifeterm of the label. The labeled compounds are useful for localizing serotonin transporter sites by positron emission tomography and/or single photon emission computed tomography.
REFERENCES:
patent: 4514398 (1985-04-01), Regnier et al.
patent: 4529730 (1985-07-01), Schneider et al.
patent: 4791119 (1988-12-01), Langer
patent: 5169855 (1992-12-01), Cain et al.
patent: 5296479 (1994-03-01), Cain et al.
patent: 5317024 (1994-05-01), Cain et al.
patent: 5372813 (1994-12-01), Mathis, Jr. et al.
Dhainaut et al. "Piperidinotriazinediamines" CA 100:68324, 1983.
Scatton et al. "SI. 81.0385: a novel selective and potent serotonin uptake inhibitor" CA 108:124383, 1988.
Connell et al. "Heterocyclic aryl, alkyl and cyclalkylacetic acid amide useful as antiatherosclerotics" CA 126:317323, 1997.
Wagner et al. "Principles of nuclear medicine" Sanders Co. pp. 166-177, 1995. and selective ligand for the 5-hydroxytryptamine uptake complex. II. In vivo studies in rats," Brain Res. 619:236-246.
Hume, S.P. et al. (1991), "Citalopram: Labelling with Carbon-11 and Evaluation in Rat as a Potential Radioligand for In Vivo PET Studies of 5-HT Re-uptake Sites," Nucl. Med. Biol. 18(3):339-351.
Jagust, W.J. et al. (1993), "In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed 242:189-193.
Kilbourn, M.R. et al. (1989), "Synthesis of Radiolabeled Inhibitors of Radiopharm 26:412-414.
Mathis, C. et al. (1993), "Synthesis and Biological Evaluation of a PET J. Nucl. Med. 34:7P-8P.
Mathis, C.A. et al. (1994), "Synthesis of .sup.123 I, and .sup.125 I-Labelled 5-iodo-6-nitroquipazine," J. Labelled Compounds and Radiopharm. XXXIV(10):905-913.
Mulholland, G.K. et al. (1995), "Synthesis, In vivo Biodistribution and Muscarinic Acetylcholine Receptor Antagonist," Nucl. Med. Biol. 22(1):13-17.
Maryanoff, B.E. et al. (1987), "Pyrroloisoquinoline Antidepressants. 2. In-Depth Exploration of Structure-Activity Relationships," J. Med. Chem. 30:1433-1454.
Suehiro, M. et al. (1990), "In Vivo Labeling of the Dopamine D2 REceptor with N-.sup.11 C-Methyl-Benperidol," J. Nucl. Med. 31(12):2015-2021. F!Fluoropropyl)paroxetine as a Radiotracer for In Vivo Labeling of Serotonin Uptake Sites by PET," Nucl. Med. Biol. 18(7):791-796.
Suehiro, M. et al. (1993), "A PET Radiotracer for Studying Serotonin Uptake Sites: Carbon-11-McN-5652Z," J. Nucl. Med. 34(1):120-127.
Faraj Bahjat
Goodman Mark M.
Chang Ceila
Emory University
LandOfFree
Halogenated naphthyl methoxy piperidines for mapping serotonin t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Halogenated naphthyl methoxy piperidines for mapping serotonin t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Halogenated naphthyl methoxy piperidines for mapping serotonin t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-899289